Dartmouth College · Microbiology & ImmunologyAlzheimer's Immune Therapeutics Lab
Charles L. Sentman · Hanover, New Hampshire
Research Focus
Dr. Charles L. Sentman's lab at Dartmouth College focuses on developing innovative therapies for Alzheimer's disease using genetically engineered immune cells. The lab's main project involves creating chimeric antigen receptor (CAR) T regulatory cells that can target and clear harmful amyloid-beta protein plaques in the brain, while reducing inflammation associated with the disease. By enhancing the persistence and activity of these targeted cells, the goal is to improve treatments for Alzheimer's and its neurodegenerative effects.
Alzheimer's diseaseCAR Tregsneuroinflammationimmune therapyamyloid-betaT regulatory cellscell engineeringcentral nervous systeminflammation modulation
Research Aims
5AIM 01Develop CAR T regulatory cells that target amyloid-beta plaques in Alzheimer's disease.
AIM 02Investigate the impact of engineered Tregs on neuroinflammation and neuronal damage.
AIM 03Assess the long-term persistence and therapeutic effects of Tregs in the CNS.
AIM 04Explore the interactions between Tregs and microglial cells in cognitive decline.
AIM 05Evaluate potential side effects of Treg therapy on brain function.
Skills the Lab Values
Cell cultureCAR T cell engineeringFlow cytometryPCRMolecular cloningAnimal modelsNeurobehavioral assaysImmunofluorescenceData analysisIn vivo experimentation
Output against the department
Publications216top 29% of dept.142nd of 486
this lab
most publishedleast published
Citations9.5ktop 38% of dept.186th of 486
this lab
most citedleast cited
Career totals from OpenAlex, compared against labs that share a department. A department spans everything from one paper to tens of thousands, so bar heights are on a log scale — otherwise the largest lab would flatten every other bar to a line.